Weerawat Manosuthi - Concepedia

Author

Weerawat Manosuthi

Bamrasnaradura Infectious Diseases Institute ORCID

Also Known As

Ariel E Zuckerman, Manosuthi W, Manosuthi, Weerawat, Naphassanant Laopraynak, Pompeyo Viciana Fernández, Suwimon Khusuwan, T Anekthananon, W MANOSUTHI, W Manosuthi, W Manosuthi, MD

177

Publications

4.3K

Citations

H-Index

Concepts

All Affiliations

Bamrasnaradura Infectious Diseases Institute Ministry of Public Health Mahidol University Ramathibodi Hospital Chulalongkorn University

About

Weerawat Manosuthi is an author at Bamrasnaradura Infectious Diseases Institute specializing in medicine, hiv, and epidemiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	24	1.2K
2	Public Health	10	10	324
3	Epidemiology	10	11	344
4	Global Health	2	2	25
5	Health Sciences	1	1	22

Weerawat Manosuthi

Publications

3.5K

Citations

H-Index

Page 1

	Year	Citations
Survival Rate and Risk Factors of Mortality Among HIV/Tuberculosis-Coinfected Patients With and Without Antiretroviral Therapy Weerawat Manosuthi, Suthat Chottanapand, Supeda Thongyen, JAIDS Journal of Acquired Immune Deficiency Syndromes	2006	257
HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients Soranun Chantarangsu, Taisei Mushiroda, Surakameth Mahasirimongkol, Pharmacogenetics and Genomics	2009	187
Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy Weerawat Manosuthi, Sasisopin Kiertiburanakul, Thanongsri Phoorisri, Journal of Infection Primary ImmunodeficiencyPulmonary TuberculosisAntiretroviral TherapyAutoimmune DiseaseImmunodeficiencies	2006	147
A Phase II Randomized Trial of Amphotericin B Alone or Combined with Fluconazole in the Treatment of HIV‐Associated Cryptococcal Meningitis Peter G. Pappas, Ploenchan Chetchotisakd, Robert A. Larsen, Clinical Infectious Diseases	2009	146
A Randomized Trial Comparing Plasma Drug Concentrations and Efficacies between 2 Nonnucleoside Reverse‐Transcriptase Inhibitor–Based Regimens in HIV‐Infected Patients Receiving Rifampicin: The N<sub>2</sub>R Study Weerawat Manosuthi, Somnuek Sungkanuparph, Preecha Tantanathip, Clinical Infectious Diseases	2009	114
Cryptococcal Immune Reconstitution Inflammatory Syndrome after Antiretroviral Therapy in AIDS Patients with Cryptococcal Meningitis: A Prospective Multicenter Study Somnuek Sungkanuparph, S. G. Filler, Ploenchan Chetchotisakd, Clinical Infectious Diseases ImmunodeficienciesImmunologyPathologyProspective Multicenter StudyInflammation	2009	111
Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results Weerawat Manosuthi, Sasisopin Kiertiburanakul, Somnuek Sungkanuparph, AIDS Drug InteractionsTreatment And PreventionPharmacologyAntiviral TherapyTuberculosis	2005	108
Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand Weerawat Manosuthi, Sumet Ongwandee, Sorakij Bhakeecheep, AIDS Research and Therapy ImmunodeficienciesTuberculosis PreventionImmunologyAntiviral DrugAdolescents 2014	2015	95
Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial John H. Beigel, Yajing Bao, Joy Beeler, The Lancet Infectious Diseases Antiviral Drug DevelopmentAntiviral TherapyVirologyPharmacotherapyInfection Control	2017	94
Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin Weerawat Manosuthi, Somnuek Sungkanuparph, Ammarin Thakkinstian, AIDS	2005	84

Page 1